Evaluation of Neurodevelopmental Outcomes in Children Aged 4-8 Years Related to Gestational Xylitol Exposure in Malawi
Led by University of Washington · Updated on 2026-08-19
1000
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying neurodevelopmental outcomes in children aged 4 to 8 years in Malawi who were born to mothers participating in the Prevention of Prematurity and Xylitol PPaX trial. This study compares children exposed to maternal xylitol chewing gum during pregnancy to those without such exposure, focusing on cognitive, executive function, social-emotional, motor, and language development. The trial includes 1000 children divided equally between formerly preterm and term births, considering the impact of gestational xylitol exposure on these groups.
The study does not involve new treatments but evaluates differences based on prior exposure to xylitol chewing gum during pregnancy. Children are stratified into four groups depending on preterm or term birth status and xylitol exposure. Neurodevelopmental assessments include the Malawi Developmental Assessment Tool MDAT, Kaufman Assessment Battery for Children-II KABC-II, EF Touch, Strengths and Difficulties Questionnaire SDQ, Anchor Items in Measuring Early Childhood Development AIM-ECD, and the International Development and Early Learning Assessment IDELA. Mothers may also be invited for anthropometric and oral health assessments.
Participants will undergo one to two clinic visits within one month for neurodevelopmental assessments, hearing, vision, and dental evaluations. Researchers will measure cognitive scores, executive function, social-emotional outcomes, and motor skills using standardized tools. The primary outcome is the overall cognitive score based on the mental processing index. The study monitors these outcomes carefully to understand the effects of gestational xylitol exposure on child development up to age 8.
CONDITIONS
Brief Title
Prevention of Developmental Delay and Xylitol (PDDaX) Study
Research Team
G
Greg Valentine, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Child born during the Prevention of Prematurity and Xylitol (PPaX) trial
Age between 4 and 8 years at enrollment
Parental or legal guardian consent obtained
Child willing to undergo neurodevelopmental assessments
Willingness to travel to BCMF for assessments
Assent from the child participant
You will not qualify if you...
Parent or legal guardian unable to provide informed consent
Child unwilling to provide assent for participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits
Assessment
Duration - Up to 1 month
Participants undergo neurodevelopmental, hearing, vision, and dental assessments using several standardized tools to evaluate cognition, executive function, social-emotional skills, and motor abilities.
1 to 2 clinic visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Similar Trials
Feasibility Study of an 8-Week Parent-Child Yoga Program to Improve Attention in Children Aged 4 to 6 with Congenital Heart Disease
Prospective Birth Cohort Study on Allergies and Neurodevelopmental Disorders in Infants and Young Children in China
Pilot Study on Gene Activity Changes Linked to Antipsychotic-Related Metabolic Issues in Children and Teens aged 5 to 17
Comparing Ampicillin With and Without Azithromycin for Women With Late Preterm Premature Rupture of Membranes Between 34 and 36.6 Weeks
Balanced Growth Study on How the Vestibular System Affects Motor and Cognitive Development in Children Ages 6 to 13
Study of Caffeine Citrate Treatment in Late Preterm Infants With Respiratory Distress to Reduce Respiratory Support Duration
Study of Social Cognition in Children and Teens With Neurodevelopmental Disorders Using a Multidimensional Assessment
Testing the Calmer Therapy Bed to Support Growth and Brain Development in Preterm Infants Born at 26 to 30 Weeks in the NICU
Darbepoetin Plus Slow-Release Intravenous Iron to Reduce Blood Transfusions and Support Iron Levels and Brain Development in Preterm Infants Born Before 32 Weeks
Monitoring Infant Motor Skills and Cognitive Development Using Wearable Technology
Observing Typical and At-Risk Infants from 5 to 26 Months
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The Prevention of Developmental Delay and Xylitol (PDDaX) trial: study protocol of a nested cohort follow-up from the PPaX (Prevention of Prematurity and Xylitol) trial examining neurodevelopmental outcomes among offspring at 4-8 years of age in Malawi.
Gregory C Valentine, Brent Collett, Shaphil Wallie...